Strantas 250Mg/5Ml Inj Substitute
Zydus Healthcare Ltd
₹6089
(₹1217.8/ 1ml)
Samarth Life Sciences Pvt Ltd
₹8903.5
(₹1780.7/ 1ml)
Glenmark Pharmaceuticals Ltd
₹10116.5
(₹2023.3/ 1ml)
Admac Lifesciences(Oncology)
₹10995
(₹2199.0/ 1ml)
Cadila Pharmaceuticals Ltd
₹12666.5
(₹2533.3/ 1ml)
Aureate Healthcare
₹14531
(₹2906.2/ 1ml)
Intas Pharmaceuticals Ltd
₹14600
(₹2920.0/ 1ml)
Emcure Pharmaceuticals Ltd
₹14745
(₹2949.0/ 1ml)
Alkem Laboratories Ltd
₹16284
(₹3256.8/ 1ml)
Hetero Healthcare Pvt Ltd
₹16500
(₹3300.0/ 1ml)
Alkem Laboratories Ltd
₹17370
(₹3474.0/ 1ml)
Adley Formulations
₹20571
(₹4114.2/ 1ml)
Astra Zeneca Pharma India Ltd
₹39562
(₹7912.4/ 1ml)

Patients may explore substitutes in the following scenarios:
Before you switch from Strantas 250Mg/5Ml Inj to another medicine, here are some important points to keep in mind:
Most substitutes contain the same active ingredient - FULVESTRANT-250MG, but the fillers, coating, or manufacturing quality may vary slightly.
Even if the salt is the same, your doctor can confirm if the substitute is right for your condition, dosage, and health history.
Some people may react differently to certain brands due to inactive ingredients. If you notice any side effects, inform your doctor immediately.
A lower-priced substitute doesn't mean it's less effective. Many generic medicines work just as well as branded ones.
Always match the substitute’s strength (e.g., 5mg, 10mg) and form (tablet, capsule, syrup) with what your doctor prescribed.
Strantas 250Mg/5Ml Inj is used in the treatment of Breast cancer in postmenopausal women. The detailed uses of Strantas 250Mg/5Ml Inj are as follows:
Strantas 250Mg/5Ml Inj contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Strantas 250Mg/5Ml Inj may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).
RX